Repaglinide

규격

135062-02-1CAS 번호

629-921-1EC 번호

2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acidIUPAC 명칭

C27H36N2O4화학식

452.6 g/mol분자량

Repaglinide; 135062-02-1; Prandin; Repaglinida; AG-EE 623 ZW; GlucoNorm; AG-EE 388 ZW; Repaglinidum; AGEE-623ZW; enyglid; AG-EE-623ZW; DTXSID3023552; 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid; NSC-759893; AG-EE-623-ZW; A10BX02; 668Z8C33LU; DTXCID603552; (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid; repaglinide impurity E; 2-ethoxy-4-({[(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]carbamoyl}methyl)benzoic acid; Benzoic acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-, (S)-; repa-glinide; 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid; AG-EE 388; 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid; (+)-repaglinide; 2-ethoxy-4-((((1S)-3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)carbamoyl)methyl)benzoic acid; 2-ethoxy-4-(2-(((1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl)amino)-2-oxoethyl)benzoic acid; RefChem:56406; 2-ethoxy-N-(alpha-(2-methyl-1-propyl)-2-piperidinobenzyl)-4-carbamoylmethylbenzoic acid; (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; 2-ethoxy-4-(2-(((1R)-3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid; 629-921-1; Benzoic Acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-,(S)-; NovoNorm; (S)-2-Ethoxy-4-(2-((3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid; Repaglinidum [INN-Latin]; Repaglinida [INN-Spanish]; C27H36N2O4; MFCD00906179; AG-EE 623ZW; (S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid; CHEMBL1272; (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid; (S)-2-ethoxy-4-(2-(3-methyl-1-(2-(piperidin-1-yl)phenyl)butylamino)-2-oxoethyl)benzoic acid; 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid; NCGC00016978-01; Repaglinide [USAN]; CAS-135062-02-1; Actulin; Surepost; (-)-Repaglinide; Reglin; (S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidyl)phenyl]butyl]amino]-2-oxoethyl]benzoic Acid; SMR000466305; Prandin (TN); Repaglinide (JAN/USP/INN); UNII-668Z8C33LU; AG-EE-623 ZW; Novonorm;; Repaglinide CRS; AG-EE-388; SMP-508; Surepost (TN); BJX; Repaglinide [USAN:USP:INN:BAN]; NN-623; REPAGLINIDE KRKA; REPAGLINIDE TEVA; Repaglinide (Standard); 111GE012; REPAGLINIDE ACCORD; REPAGLINIDE [MI]; Prestwick0_001046; Prestwick1_001046; Prestwick2_001046; Prestwick3_001046; REPAGLINIDE [INN]; REPAGLINIDE [JAN]; REPAGLINIDE [VANDF]; (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; REPAGLINIDE [MART.]; SCHEMBL16137; BSPBio_000972; REPAGLINIDE [USP-RS]; REPAGLINIDE [WHO-DD]; MLS000759407; MLS001076684; MLS001424111; MLS006011560; BIDD:GT0338; SPBio_002906; REPAGLINIDE [EMA EPAR]; BPBio1_001070; CHEBI:8805; GTPL6841; orb1226478; orb1309813; Repaglinide - Bio-X trade mark; SCHEMBL29373506; SCHEMBL29392295; AG-EE-623; MSK7195; REPAGLINIDE [ORANGE BOOK]; GLXC-05202; HMS1571A14; HMS2051N08; HMS2094C07; HMS2098A14; HMS2231M21; HMS3414D09; HMS3678D09; HMS3715A14; Pharmakon1600-01506035; REPAGLINIDE [EP MONOGRAPH]; REPAGLINIDE [USP MONOGRAPH]; Tox21_110721; AC-726; BDBM50153520; EBC-06064; HB1106; HY-15209R; MSK7195-100A; NSC759893; STK629501; AKOS005561792; MSK7195-1000A; Repaglinide for system suitability CRS; Repaglinide, >=98% (HPLC), solid; BS-1010; CCG-101013; CS-0979; DB00912; FR27699; NC00263; NSC 759893; NCGC00016978-02; NCGC00016978-04; NCGC00016978-05; NCGC00016978-12; NCGC00016978-15; REPAGLINIDE COMPONENT OF PRANDIMET; (S)-2-Ethoxy-4-[2-[[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic Acid; 2-ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidyl)phenyl]butyl]amino]-2-oxo-ethyl]benzoic acid; BR164332; HY-15209; SY046828; SBI-0206942.P001; AB00514019; R0179; R1860; SW197344-4; C07670; D00594; F15001; Repaglinide Solution in Acetonitrile, 100ug/mL; AB00514019-09; AB00514019_10; AB00514019_11; Repaglinide Solution in Acetonitrile, 1000ug/mL; F805634; SR-01000759404; Q2195995; SR-01000759404-4; BRD-K82846253-001-03-0; BRD-K82846253-001-14-7; BRD-K82846253-001-15-4; BRD-K82846253-001-16-2; Z1501485370; Repaglinide, European Pharmacopoeia (EP) Reference Standard; Repaglinide, United States Pharmacopeia (USP) Reference Standard; (s)-(+)-2-ethoxy-4-(2-oxo-2-[(alpha-isobutyl-2-piperidinobenzyl)amino]ethyl)-benzoic acid; Repaglinide for system suitability, European Pharmacopoeia (EP) Reference Standard; (+)-2-ETHOXY-.ALPHA.-(((S)-.ALPHA.-ISOBUTYL-O-PIPERIDINOBENZYL)CARBAMOYL)-P-TOLUIC ACID; (S)-2-Ethoxy-4-(2-((3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzoicacid; (S)-2-ETHOXY-4-(2-(METHYL-1-(2-(1-PIPERIDINYL)PHENYL)BUTYLAMINO)-2-OXOETHYL)-BENZOIC ACID; (S)-2-Ethoxy-4-[N-(1-(2-piperidino-phenyl)-3-methyl-1-butyl)-aminocarbonylmethyl]-benzoic acid; 2-Ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benz oic acid; 2-Ethoxy-4-{[(S)-3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoic acid동의어